Sanofi
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Clarivate Identifies Thirteen Potential Blockbuster Drugs
Clarivate's 2024 Drugs to Watch report highlights 13 new therapeutics expected to achieve blockbuster status by 2029, targeting conditions like sickle cell disease, RSV, and breast cancer. It also notes the growing chronic disease market in China and the impact of new technologies like CRISPR-Cas9 and AI in drug development.
Tonix Pharmaceuticals Appoints Gary Ainsworth as VP of Market Access for TNX-102 SL's Fibromyalgia Treatment
Tonix Pharmaceuticals appointed Gary Ainsworth as VP of Market Access, leveraging his extensive experience for TNX-102 SL's potential fibromyalgia treatment approval by August 15, 2025. Ainsworth's role aims to enhance market access strategies, supporting the drug's commercial launch.
Totus Medicines Closes $66M Series B Funding
Totus Medicines secured $66M in Series B funding led by DCVC Bio, with contributions from North Pond Ventures, Camford Capital, and the University of Minnesota. The funds will advance clinical programs, expand the pipeline, and evolve their AI-driven drug discovery platform. Nassim Usman, Ph.D., was appointed President & CEO, with Neil Dhawan, Ph.D., transitioning to CSO and Head of R&D.
Type 1 Diabetes (T1D) Market: Global Industry Analysis
The global Type 1 Diabetes (T1D) market is projected to grow at a CAGR of 17.2%, reaching US$ 38.63 Bn by 2029. Driven by increased awareness, technological advancements in insulin delivery, and government initiatives, the market faces challenges like high costs and biosimilars. North America leads, with APAC expected to grow significantly.
Biotechnology Market is Expanding USD 3995.22 Billion
The global biotechnology market, valued at USD 1,224.31 billion in 2022, is projected to reach USD 3,995.22 billion by 2032, growing at a 12.5% CAGR. It drives innovation in healthcare, agriculture, and environmental sustainability, with bio-pharmacy leading through precision medicine, biologics, and immuno-oncology. Despite regulatory and IP challenges, opportunities in personalized medicine and rare diseases are expanding. Key players include Novartis, Roche, and Biogen.
FDA Advisers Vote in Favor of Infant RSV Drug
AstraZeneca and Sanofi's drug, Beyfortus, for preventing RSV in infants, received unanimous FDA advisory panel support. It's a single-dose, long-acting monoclonal antibody aimed at newborns and infants during their first RSV season. The panel also supported its use for children up to two years old. The drug is already approved in the U.K., EU, and Canada.
Understanding the company landscape in AI-driven biopharma R&D
AI advancements are transforming drug discovery, with tools like AlphaFold2 enhancing protein-structure prediction. Biopharma firms are building AI capabilities through in-house expertise, acquisitions, and partnerships. Despite a decline in new AI-driven biotech companies, capital deployment has surged, with significant partnerships and some clinical trial successes. However, challenges in integration and competition persist, suggesting a future of increased M&A activity and a focus on unsaturated niches like RNA-based therapeutics.
Events - PAN Foundation Engages in Conferences and Webinars to Raise Awareness on Healthcare Access, Equity, and Affordability
The PAN Foundation engages in conferences and webinars to raise awareness on healthcare access, equity, and affordability, offering financial assistance for underinsured patients with chronic and rare diseases. Events include webinars on Medicare reforms, financial assistance for rare diseases, and family wellness festivals, aiming to connect patients with necessary resources.
How generative AI could lower healthcare costs and speed up drug development
Absci Corp. developed de novo antibodies against HER2 using zero-shot generative AI, without prior data on successful antibodies. This AI-designed antibodies, tested in a wet lab, show potential for novel cancer therapies. Absci plans to have a drug in clinical trials by 2024, marking a significant advancement in AI-driven drug discovery.
© Copyright 2025. All Rights Reserved by MedPath